Patent Snapshot: Corvus Pharma’s immune-focused drug portfolio
Highlights: Corvus Pharmaceuticals, founded in 2014, develops targeted therapies designed to modulate the immune system. Its pipeline includes Soquelitinib, Ciforadenant, and Mupadolimab. These programs focus on T cell and natural killer cell pathways, adenosine signaling, and CD73 activity. Corvus emphasizes biomarker-driven development to evaluate safety, mechanism of action, and efficacy across immune diseases and cancer.…
Read more